DE60041365D1 - Verwendung von Riluzol zur Behandlung Multipler Sklerose - Google Patents

Verwendung von Riluzol zur Behandlung Multipler Sklerose

Info

Publication number
DE60041365D1
DE60041365D1 DE60041365T DE60041365T DE60041365D1 DE 60041365 D1 DE60041365 D1 DE 60041365D1 DE 60041365 T DE60041365 T DE 60041365T DE 60041365 T DE60041365 T DE 60041365T DE 60041365 D1 DE60041365 D1 DE 60041365D1
Authority
DE
Germany
Prior art keywords
riluzole
treatment
multiple sclerosis
sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60041365T
Other languages
English (en)
Inventor
Chris Polman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vereniging voor Christelijk Wetenschappelijk Onderwijs
Original Assignee
Vereniging voor Christelijk Wetenschappelijk Onderwijs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging voor Christelijk Wetenschappelijk Onderwijs filed Critical Vereniging voor Christelijk Wetenschappelijk Onderwijs
Application granted granted Critical
Publication of DE60041365D1 publication Critical patent/DE60041365D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DE60041365T 1999-06-04 2000-06-02 Verwendung von Riluzol zur Behandlung Multipler Sklerose Expired - Lifetime DE60041365D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04

Publications (1)

Publication Number Publication Date
DE60041365D1 true DE60041365D1 (de) 2009-02-26

Family

ID=26153326

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041365T Expired - Lifetime DE60041365D1 (de) 1999-06-04 2000-06-02 Verwendung von Riluzol zur Behandlung Multipler Sklerose

Country Status (5)

Country Link
US (3) US6872739B1 (de)
JP (1) JP2007262082A (de)
AU (1) AU2005200244A1 (de)
DE (1) DE60041365D1 (de)
HK (1) HK1076049A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017733T2 (de) * 1999-06-04 2006-01-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von riluzol zur behandlung multipler sklerose
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US20070244056A1 (en) * 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
ATE440888T1 (de) * 2004-10-29 2009-09-15 Sandoz Ag Verfahren zur herstellung von glatiramer
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
ES2819303T3 (es) * 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826860A (en) 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
FR2688138B1 (fr) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5617861A (en) * 1994-02-16 1997-04-08 Huntington Medical Research Institutes Magnetic resonance spectral analysis of the brain for diagnosis of clinical conditions
WO1997015306A1 (en) * 1995-10-25 1997-05-01 Janssen Pharmaceutica N.V. Infusions of neuroprotectants and perfluorochemicals
ATE248598T1 (de) * 1995-11-15 2003-09-15 Yamanouchi Pharma Co Ltd Inhibitoren der kainsäure-neurotoxizität sowie pyridothiazinderivate
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US5780489A (en) * 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
CA2200045A1 (en) * 1997-03-14 1998-09-14 Neil Cashman A method of evaluating the efficacy of drug on brain nerve cells
JP4120713B2 (ja) * 1997-09-04 2008-07-16 大塚製薬株式会社 多発性硬化症治療剤
FR2774592B1 (fr) 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
US20030077641A1 (en) * 1998-03-11 2003-04-24 Laskowitz Daniel T. Methods of suppressing microglial activation and systemic inflammatory responses
US7060457B2 (en) 1998-03-18 2006-06-13 Johns Hopkins University Aberrant glutamate transporters and methods of use
JP2002510604A (ja) 1998-04-02 2002-04-09 アビセナ グループ， インク． クレアチン化合物及び第二物質の組み合わせを含む組成
FR2777781B1 (fr) 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
DE60017733T2 (de) * 1999-06-04 2006-01-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von riluzol zur behandlung multipler sklerose
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
IL136687A0 (en) 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
HK1076049A1 (en) 2006-01-06
US20080214631A1 (en) 2008-09-04
AU2005200244A1 (en) 2005-02-17
US20050171168A1 (en) 2005-08-04
US7342033B2 (en) 2008-03-11
US6872739B1 (en) 2005-03-29
JP2007262082A (ja) 2007-10-11

Similar Documents

Publication Publication Date Title
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE69903543T2 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE254913T1 (de) Diacerein zur behandlung von psoriasis
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60038458D1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60041365D1 (de) Verwendung von Riluzol zur Behandlung Multipler Sklerose
DE60103078D1 (de) Chemokin mutanten zur behandlung multipler sklerose
DE69939723D1 (de) Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE60017733D1 (de) Verwendung von riluzol zur behandlung multipler sklerose
ATE433323T1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression

Legal Events

Date Code Title Description
8364 No opposition during term of opposition